Biomarkers for Prediction of Tumor Response to Radiotherapy

ConditionSolid Tumors

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorChuangzhen Chen

About this trial

This study aims to explore potential biomarkers for prediction of therapeutic outcomes in patients with solid tumors after radiotherapy

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pathological proven diagnosis of solid tumors

Tumor accessible for biopsy during the course of radiotherapy or tumor samples could be obtained via surgery

Patient must provide study-specific informed consent prior to study entry

Disqualifiers

History of autoimmune diseases

History of immunotherapy

Prior radiation therapy that would result in overlap of planned radiation therapy fields

Will receive immunotherapy during the course of radiotherapy

Trial population

Patients proven diagnosis of solid tumors and will have radiotherapy as part of their therapeutic regimens or will undergo surgery in Cancer Hospital of Shantou University Medical College.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

Expression status of biomarkers and their dynamic changes during treatment and follow-up

Expression status of biomarkers and their dynamic changes in patients' biological specimens through the course of treatment and during follow-up as assessed by a variety of means, including RNA-seq, DNA-seq, RT-qPCR, IHC, WB and ELISA.

Time frame

From the date of enrollment until the date of disease progression, assessed up to 3 years

Tumor short-term response to therapeutics

For patients treated with radiotherapy, shortly after the completion of treatment, the short-term response was assessed by using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) .

Time frame

Within 1 month after the completion of radiotherapy

Tumor long-term response to therapeutics

For patients treated with radiotherapy, tumor response was assessed by using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) .

Time frame

up to 3 years of follow-up

Secondary outcomes

Disease-specific survival

The tumor disease-specific survival of patients

Time frame

up to 3 years of follow-up

Other outcomes

Overall survival

The overall survival of patients

Time frame

up to 3 years of follow-up

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chuangzhen Chen

Lead sponsor

Shantou University Medical College

Sponsor institution

University of Oxford

Collaborator

Source ClinicalTrials.gov

Apply now